# Evolent Health Inc (EVH) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Providers & Services. Price $4.32, market value $488 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Evolent Health Inc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 0.2×**. Each dollar of revenue is priced at 0.2×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.

## Profitability
- **Operating margin: -20.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -28.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -128.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -27.4%**. Return on all capital, debt included, is -27.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -26.6%**. Each dollar of assets produces -26.6% of profit.

## Growth
- **Revenue growth (1 yr): -26.6%** (3-yr 11.5%/yr, 5-yr 15.2%/yr). Revenue fell 26.6% over the last year, against 15.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -525.9%**. Earnings per share fell 525.9%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 2.34**. Debt is 2.34 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Evolent Health Inc holds more cash than debt.
- **Altman Z-score: 0.78**. A Z-score of 0.78 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Evolent Health Inc does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover Evolent Health Inc; the consensus is buy, with an average price target of $5.77 (+34% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -54.5%** (YTD 8.0%, 3-mo 2.4%). The shares are down 54.5% over twelve months including dividends.
- **From 52-week high: -57.1%** (106.2% above the low). Trading 57% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 0.87** (volatility 81%). Beta of 0.87 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EVH · Page: https://foliofundamentals.com/stocks/evh

Not investment advice.